CL2016002469A1 - Sulfamidasa modificada y su producción - Google Patents
Sulfamidasa modificada y su producciónInfo
- Publication number
- CL2016002469A1 CL2016002469A1 CL2016002469A CL2016002469A CL2016002469A1 CL 2016002469 A1 CL2016002469 A1 CL 2016002469A1 CL 2016002469 A CL2016002469 A CL 2016002469A CL 2016002469 A CL2016002469 A CL 2016002469A CL 2016002469 A1 CL2016002469 A1 CL 2016002469A1
- Authority
- CL
- Chile
- Prior art keywords
- sulfamidase
- modified sulfamidase
- modified
- production
- dich
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>En el presente documento, se divulga una sulfamidasa modificada, una composición que comprende una sulfamidasa modificada y métodos de preparación de una sulfamidasa modificada y uso terapéutico de dicha sulfamidasa. Específicamente, la presente divulgación se relaciona con una sulfamidasa modificada que prácticamente no comprende epítopos para los receptores de reconocimiento de glicanos, permitiendo así el transporte de dicha sulfamidasa a través de la barrera hematoencefálica de un mamífero, donde dich</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14162996 | 2014-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002469A1 true CL2016002469A1 (es) | 2017-12-15 |
Family
ID=50389999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002469A CL2016002469A1 (es) | 2014-04-01 | 2016-09-30 | Sulfamidasa modificada y su producción |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9982243B2 (es) |
| EP (2) | EP2970413B1 (es) |
| JP (1) | JP6594896B2 (es) |
| KR (1) | KR20160138282A (es) |
| CN (1) | CN106414727A (es) |
| AU (1) | AU2015239126B2 (es) |
| BR (1) | BR112016022333A2 (es) |
| CA (1) | CA2943140A1 (es) |
| CL (1) | CL2016002469A1 (es) |
| CY (1) | CY1120697T1 (es) |
| DK (1) | DK2970413T3 (es) |
| ES (1) | ES2687262T3 (es) |
| HK (1) | HK1231510A1 (es) |
| HR (1) | HRP20181507T1 (es) |
| HU (1) | HUE039691T2 (es) |
| IL (1) | IL247978A0 (es) |
| LT (1) | LT2970413T (es) |
| MA (1) | MA38816B1 (es) |
| MX (1) | MX368947B (es) |
| PH (1) | PH12016501812A1 (es) |
| PL (1) | PL2970413T3 (es) |
| PT (1) | PT2970413T (es) |
| RS (1) | RS57842B1 (es) |
| RU (1) | RU2708026C2 (es) |
| SA (1) | SA516371859B1 (es) |
| SG (1) | SG11201608025QA (es) |
| SI (1) | SI2970413T1 (es) |
| UA (1) | UA120432C2 (es) |
| WO (1) | WO2015150490A1 (es) |
| ZA (1) | ZA201606492B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160138282A (ko) | 2014-04-01 | 2016-12-02 | 스위디쉬 오르펀 바이오비트럼 에이비(피유비엘) | 변형된 설프아미다제 및 그의 제조 |
| CA3000289A1 (en) * | 2015-10-01 | 2017-04-06 | Swedish Orphan Biovitrum Ab (Publ) | Modified lysosomal protein and production thereof |
| JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 酵素補充療法用酵素を含む融合タンパク質 |
| WO2019145500A1 (en) | 2018-01-26 | 2019-08-01 | Swedish Orphan Biovitrum Ab (Publ) | Method of treatment |
| US11708569B2 (en) | 2018-08-29 | 2023-07-25 | University Of Copenhagen | Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid |
| EP3741867A1 (en) | 2019-05-24 | 2020-11-25 | Swedish Orphan Biovitrum AB (Publ) | Sulfatase activity assay |
| WO2022081765A1 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| DE69724428T3 (de) | 1996-06-07 | 2009-07-23 | Poniard Pharmaceuticals, Inc., Seattle | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2003251770B9 (en) | 2002-07-01 | 2009-06-04 | H. Lundbeck A/S | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| WO2008109677A2 (en) * | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
| LT2245145T (lt) * | 2008-01-18 | 2017-04-10 | Biomarin Pharmaceutical Inc. | Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas |
| EP2394667A1 (en) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vectors and sequences for the treatment of diseases |
| ES2661967T3 (es) * | 2010-12-22 | 2018-04-04 | Fondazione Telethon | Estrategias terapéuticas para tratar patologías del SNC en mucopolisacaridosis |
| JP6175431B2 (ja) * | 2011-06-20 | 2017-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法 |
| WO2014194427A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted iduronate-2-sulfatase fusion proteins |
| US20140377246A1 (en) | 2013-06-19 | 2014-12-25 | Carol Ann Foundation and International Morquio Organization | Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme |
| KR20160138282A (ko) | 2014-04-01 | 2016-12-02 | 스위디쉬 오르펀 바이오비트럼 에이비(피유비엘) | 변형된 설프아미다제 및 그의 제조 |
-
2015
- 2015-04-01 KR KR1020167030393A patent/KR20160138282A/ko unknown
- 2015-04-01 EP EP15713502.1A patent/EP2970413B1/en active Active
- 2015-04-01 JP JP2016560417A patent/JP6594896B2/ja not_active Expired - Fee Related
- 2015-04-01 RU RU2016140844A patent/RU2708026C2/ru not_active IP Right Cessation
- 2015-04-01 SI SI201530397T patent/SI2970413T1/sl unknown
- 2015-04-01 CN CN201580026957.6A patent/CN106414727A/zh active Pending
- 2015-04-01 PT PT15713502T patent/PT2970413T/pt unknown
- 2015-04-01 RS RS20181119A patent/RS57842B1/sr unknown
- 2015-04-01 BR BR112016022333A patent/BR112016022333A2/pt not_active Application Discontinuation
- 2015-04-01 UA UAA201610956A patent/UA120432C2/uk unknown
- 2015-04-01 PL PL15713502T patent/PL2970413T3/pl unknown
- 2015-04-01 DK DK15713502.1T patent/DK2970413T3/en active
- 2015-04-01 MA MA38816A patent/MA38816B1/fr unknown
- 2015-04-01 WO PCT/EP2015/057256 patent/WO2015150490A1/en active Application Filing
- 2015-04-01 HU HUE15713502A patent/HUE039691T2/hu unknown
- 2015-04-01 ES ES15713502.1T patent/ES2687262T3/es active Active
- 2015-04-01 LT LTEP15713502.1T patent/LT2970413T/lt unknown
- 2015-04-01 SG SG11201608025QA patent/SG11201608025QA/en unknown
- 2015-04-01 CA CA2943140A patent/CA2943140A1/en not_active Abandoned
- 2015-04-01 AU AU2015239126A patent/AU2015239126B2/en not_active Ceased
- 2015-04-01 MX MX2016012910A patent/MX368947B/es active IP Right Grant
- 2015-04-01 EP EP18180516.9A patent/EP3401325A1/en not_active Withdrawn
- 2015-07-22 US US14/806,504 patent/US9982243B2/en active Active
-
2016
- 2016-09-16 PH PH12016501812A patent/PH12016501812A1/en unknown
- 2016-09-19 SA SA516371859A patent/SA516371859B1/ar unknown
- 2016-09-20 ZA ZA2016/06492A patent/ZA201606492B/en unknown
- 2016-09-22 IL IL247978A patent/IL247978A0/en unknown
- 2016-09-30 CL CL2016002469A patent/CL2016002469A1/es unknown
-
2017
- 2017-05-23 HK HK17105213.1A patent/HK1231510A1/zh unknown
-
2018
- 2018-04-27 US US15/965,597 patent/US20180320152A1/en not_active Abandoned
- 2018-09-24 CY CY181100983T patent/CY1120697T1/el unknown
- 2018-09-24 HR HRP20181507TT patent/HRP20181507T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| GT201700146A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| EA201792613A1 (ru) | Модуляторы cot и способы их применения | |
| CR20150502A (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización | |
| GT201400297A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| PE20151921A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos | |
| AR097481A1 (es) | Cocristales energéticos para el tratamiento de una formación subterránea | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| AR093788A1 (es) | Inmunoterapia con agentes de enlace | |
| CL2014001853A1 (es) | Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario. | |
| CL2017000506A1 (es) | Nuevos anticuerpos anti-mfi2 y metodos de uso | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| BR112016018654A2 (pt) | Composições de silicato estabilizadas e seu uso como composições antiperspirantes | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| UY36455A (es) | Antagonistas del receptor ep3 de prostaglandinas | |
| UY35776A (es) | ?antagonistas de receptor ep3 de prostaglandina?. | |
| UY34842A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| ECSP16096831A (es) | Derivados de naftiridinadiona |